2026 Volume 73 Issue 3.4 Pages 419-424
Objective:Once-daily teriparatide (1/d-TPTD) and twice-weekly teriparatide (2/w-TPTD) have high clinical efficacy, but adherence and persistence with treatment remain limited. We introduced a novel strategy involving a transition from 6 months of 1/d-TPTD to 6 months of 2/w-TPTD, which we first defined as “teriparatide-switch therapy” (TST). This study aimed to clarify the effectiveness and safety of TST. Methods:The study had a single-arm observational pre–post design and included 38 women with primary osteoporosis. Following 6 months of 1/d-TPTD, they received an additional 6 months of 2/w-TPTD. The incidence of new fractures, safety, and changes in bone mineral density (BMD) and bone turnover markers (BTMs) were recorded. Results:No new fractures occurred during TST. One patient (2.6%) experienced a non-serious adverse event (nausea) after switching to 2/w-TPTD and discontinued treatment. The percent change in BMD was +3.9% at the spine and +0.1% at the total hip at 6 months and +8.2% and +2.2%, respectively, at 12 months. Percent changes in BTMs declined gradually to baseline after switching to 2/w-TPTD. Conclusion:TST was safe and effective in women with treatment-naïve primary osteoporosis. This novel treatment strategy may improve teriparatide continuation rates and help to achieve the treatment goal of fracture prevention. J. Med. Invest. 73 : 419-424, August, 2026